STAT Plus: Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer
The positive outcome could help reverse the pessimism about the breast cancer drug that has weighed heavily on Immunomedics.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario